Kardigan is a heart health company developing personalized medicines aimed at making cardiovascular disease curable, preventable, and no longer the leading cause of death. Launched in January 2025 by veterans of MyoKardia (acquired by Bristol Myers Squibb for ~$13B in 2020), Kardigan is advancing a late-stage clinical portfolio targeting underlying drivers of specific cardiovascular diseases. Its three lead programs are danicamtiv (licensed from Bristol Myers Squibb) for genetic dilated cardiomyopathy, tonlamarsen (licensed from Ionis) for acute severe hypertension, and ataciguat (developed by Sanofi and Mayo Clinic) for calcific aortic valve stenosis. The company combines a precision-medicine clinical strategy with digital health and patient-data tools, operating from offices in South San Francisco and Princeton, NJ.
Kardigan is publicly traded
IPO'd on Jun 17, 2026
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2025
Employees
60–150
Total Funding
$954M
3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $954M across 3 rounds
Last updated 06-25-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Jun 17, 2026 | IPO | $400M | — | Not disclosed |
| Oct 14, 2025 | Series B Press release | $254M | — | Fidelity Management & Research Company |
| Jan 10, 2025 | Series A | $300M | — | Perceptive Advisors, ARCH Venture Partners, Sequoia Heritage |
Tassos Gianakakos
Co-Founder, CEO and Chair
Jay Edelberg
Co-Founder and Chief Medical Officer
Robert McDowell
Co-Founder and Chief Scientific Officer
Leslie Leinwand
Co-Founder
Elizabeth McNally
Co-Founder
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Cytokinetics
Public cardiovascular biotech developing muscle-activating therapies including aficamten, a cardiac myosin inhibitor for hypertrophic cardiomyopathy that competes directly in the genetic cardiomyopathy space targeted by Kardigan's danicamtiv.
BridgeBio Pharma
Public genetic disease company with cardiovascular focus, including acoramidis for ATTR cardiomyopathy, overlapping with Kardigan's precision cardiovascular medicine approach.
Tenaya Therapeutics
Public biotech developing gene therapies and small molecules for genetic and acquired heart disease, including dilated and hypertrophic cardiomyopathies that overlap Kardigan's target indications.
Lexeo Therapeutics
Clinical-stage genetic medicine company advancing AAV-based gene therapies for cardiovascular diseases including arrhythmogenic and Friedreich's ataxia cardiomyopathy, competing in the precision cardiac medicine space.
Ionis Pharmaceuticals
Public RNA-targeted therapeutics company that out-licensed tonlamarsen (one of Kardigan's lead programs) but also retains a broad internal cardiovascular pipeline including ASO programs for lipid and cardiovascular disorders.
Edgewise Therapeutics
Public clinical-stage biotech developing precision medicines for severe muscle disorders, including a cardiovascular pipeline targeting hypertrophic and dilated cardiomyopathies similar to Kardigan's focus.
Kardigan is an early-stage clinical biotech that emerged from stealth in January 2025 with a $300M Series A and a late-stage clinical portfolio. With three programs in or approaching pivotal cardiovascular trials and a founding team that previously took MyoKardia public before its $13B BMS acquisition, the company is a credible long-term IPO or strategic acquisition candidate, but no exit path has been publicly disclosed and it remains early in its capital lifecycle.
Kardigan shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Kardigan went public in Jun 17, 2026 via ipo. Kardigan is an early-stage clinical biotech that emerged from stealth in January 2025 with a $300M Series A and a late-stage clinical portfolio. With three programs in or approaching pivotal cardiovascular trials and a founding team that previously took MyoKardia public before its $13B BMS acquisition, the company is a credible long-term IPO or strategic acquisition candidate, but no exit path has been publicly disclosed and it remains early in its capital lifecycle.
Kardigan raised $954M across 3 disclosed funding rounds prior to its public listing.
Kardigan was co-founded by Tassos Gianakakos, Jay Edelberg, Robert McDowell, and 2 others in 2025.
Kardigan is headquartered in South San Francisco, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.